FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns to pharmacology and medicine, particularly to methods of epidermal growth factor receptor (EGFR) inhibition in a body of a mammal patient by combined use of an extracellular antagonist of receptor tyrosine kinase and an intracellular antagonist of receptor tyrosine kinase. The extracellular antagonist of receptor tyrosine kinase represents an antibody inhibiting activation of receptor tyrosine kinase by interaction with an extracellular binding region of the receptor. The intracellular antagonist of receptor tyrosine kinase represents a small molecule inhibiting activation of receptor tyrosine kinase by interaction with the intracellular binding region of the receptor bearing a kinase domain, or by interaction with an intracellular protein participating in signalling events of receptor tyrosine kinase reactions. The offered invention provides pharmaceutical compositions containing the extracellular and intracellular EGFR antagonist.
EFFECT: invention provides an improved or synergic effect on tumour growth.
11 cl
